# Evaluating the Pharmacokinetics and Safety of Miricorilant

> **NCT07553663** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Corcept Therapeutics** · enrollment: 15 (estimated)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
- Non-alcoholic Fatty Liver Disease (NAFLD)

## Interventions

- **DRUG:** Miricorilant

## Key facts

- **NCT ID:** NCT07553663
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07553663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07553663, "Evaluating the Pharmacokinetics and Safety of Miricorilant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07553663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*